MAPT and Alzheimer disease: In line with these data, it has also been found that BDNF Val66Met polymorphism leads to impaired memory performance, decreased hippocampal glucose metabolism and increased Tau protein and phosphorylated Tau in CSF from patients with preclinical familiar AD [13].